Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners

You may also be interested in...



Korea’s Green Cross Receives U.S. FDA Orphan Drug Status For Elaprase Biobetter

South Korea’s Green Cross wins U.S. FDA orphan drug designation for Hunterase, its biobetter of Shire’s Elaprase to treat Hunter syndrome.

Korean Health Ministry's New Pricing System Draws Industry Criticism

SEOUL - South Korea's Ministry of Health and Welfare held a two-day forum offering a rare opportunity for Korean and foreign pharmaceutical officials to offer comments on the ministry's controversial new pricing system

Green Cross Banking On Bioreactors To Develop Biosimilars, Biobetters Faster

SEOUL - Following a deal late last year to jointly develop biopharmaceutical products through disposable bioreactors, South Korea's vaccine giant Green Cross Corp. is expanding its collaboration to sell PBS Biotech, Inc.'s bioreactors to Korean companies

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel